Compare Nuwellis Inc (NUWE) vs Onto Innovation (ONTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Onto Innovation — how do they compare? Nuwellis Inc trades at $0.8 (market cap $2.50M), while Onto Innovation trades at $277.95 (market cap $13.80B). The key difference: Onto Innovation is far larger — about 5520× Nuwellis Inc's market cap, and Onto Innovation is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| NUWE | ONTO | |
|---|---|---|
Market Cap | $2.50M | $13.80B |
Sector | Technology | Technology |
52-Week High | $164.50 | $378.45 |
52-Week Low | $0.73 | $106.04 |
Enterprise Value | -$1.21M | $13.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.7878, up 0.88% today, but remains in a bearish technical trend. The company shows strong gross margins of 69.69% and double-digit revenue growth, but faces significant profitability challenges with negative net income margins and ROE. Recent developments include a reverse stock split, new CEO appointment, and strategic partnerships expanding pediatric care footprint.
While NUWE demonstrates operational progress with revenue growth and margin improvement, persistent losses and negative cash flow present substantial risk. The mixed analyst sentiment and bearish technical indicators suggest cautious approach. Investment appeal hinges on successful execution of financial efficiency strategy and path to profitability.
ONTO Innovation trades at $281.11, up 4.89% today, with strong analyst support (12 buy ratings, 0 hold/sell) and a $392.50 consensus price target suggesting 39.6% upside. The stock shows mixed earnings performance with a recent Q2 2026 beat ($1.93 vs. $1.69 expected) but misses in prior quarters. Revenue growth remains solid at $1.01B in 2025, though net income margin compressed to 11.84%. Technical indicators are neutral with support at $277 and resistance at $284.
Outlook remains positive given robust AI-driven semiconductor demand and a $1.1B+ backlog, but high valuation multiples (P/E 105.28, P/S 12.44) leave little room for execution missteps. Key risks include fiduciary investigation news, insider selling, and reliance on semiconductor cycle strength. Institutional confidence is high with BlackRock's $2.08B recent investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Onto Innovation
Onto Innovation provides process control solutions for semiconductor manufacturing. Its inspection and metrology systems help chipmakers measure, analyze, and detect defects on wafers and advanced packages.
Read more on ONTO →
